Nonablative allogeneic hematopoietic stem cell transplantation.
During the past few years there has been an explosion of knowledge in nonablative allogeneic stem cell transplantation. This approach to transplantation relies more on the creation of "immunologic space" for engraftment rather than the more traditional approach of creating "physical space" by the application of either intensive radiation or chemical therapy. Nonablative allogeneic stem cell transplantation holds the promise of allowing powerful alloimmune responses to eradicate disease processes while minimizing the initial treatment-related morbidity and mortality, and it appears to be the necessary enabling platform by which to apply allogeneic cellular therapy. Intuitively, this approach should broaden the eligibility for potentially curative allogeneic transplantation in various disease categories, reduce initial hospitalization costs, and at the same time have a positive impact on quality of life. We review the current published data relating to this approach including the underlying principles, the preparative regimen, disease indications, preliminary results in hematologic and solid malignancies, and certain correlative immunologic evaluations.
Dansey
R D
RD
Bone Marrow Transplant Program, Barbara Ann Karmanos Cancer Institute, Department of Medicine, Wayne State University, Detroit, Michigan, USA. dansey@karmanos.org
Baynes
R D
RD
D006086:Graft vs Host Disease; D020350:Graft vs Tumor Effect; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007938:Leukemia / Q000628:therapy*; D009369:Neoplasms / Q000628:therapy; D011379:Prognosis; D011788:Quality of Life; D014184:Transplantation, Homologous